10:31 AM EST - Prometic Life Sciences Inc. : Announced that four abstracts highlighting Prometic's progress in developing PBI-4050 as a potential treatment for both acute kidney injury and chronic kidney disease is being presented at the 56th Congress of the European Renal Association - European Dialysis and Transplant Association, ending Sunday in Budapest.
shares T.PLI are trading up $0.005 at $0.03.
